BIOLASE (BIOL) Stock

LAKE FOREST, CA / ACCESSWIRE / October 1, 2024 / BIOLASE, Inc. (NASDAQ:BIOL) (the "Company"), a global leader in dental lasers, today announced that the Company and its direct domestic subsidiaries have voluntarily initiated Chapter 11 proceedings (the "Bankruptcy Petitions") in the United States Bankruptcy Court for the District of Delaware (the "Court"). BIOLASE will seek Court approval to continue operating during the proceedings and remains focused on providing its customers with its award-winning dental lasers and customer service.

LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024. "We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE.

BIOLASE, Inc. (NASDAQ: BIOL) Q1 2024 Earnings Conference Call on May 13, 2024 at 4:30 PM ET. Company representatives include Michael Polyviou, John Beaver, and Jennifer Bright. Conference call participants include Bruce Jackson and Ed Woo. Operator will begin the call in a listen-only mode.

LAKE FOREST, CA / ACCESSWIRE / March 14, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release fourth quarter and full year 2023 financial and operating results on Thursday, March 21, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Biolase (NASDAQ: BIOL ) stock is taking a beating on Friday following the release of its earnings report for the first quarter of 2023. The bad news for investors in BIOL stock is the company's earnings per share of -18 cents for the period.